Serum Institute, India's largest vaccine manufacturer, has launched a cut-price indigenously developed intranasal vaccine against H1N1 influenza.
Nasovac, which is a human, live-attenuated vaccine, has been priced at Rs160 ($3.40) per dose and can be administered to anyone over the age of three, except pregnant women
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?